Paper29946005
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Flaherty KR and 10 others. Eur Respir J, 2018. Cited by 111 papers, by iCite.
Cite this record
ConductScience Library. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Papers, record 29946005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29946005
- Disease
- idiopathic pulmonary fibrosis133 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase IV, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents, Non-Steroidal | Major topic |
| Idiopathic Pulmonary Fibrosis | Major topic |
| Indoles | Major topic |
| Pyridones | Major topic |
| Aged | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Internationality | |
| Lung | |
| Male | |
| Middle Aged | |
| Treatment Outcome | |
| Vital Capacity |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02598193 | Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 30287496 | "Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis." Kevin R. Flaherty, Charlene D. Fell, J. Terrill Huggins, Hilario Nunes, Robert Sussman, Claudia Valenzuela, Ute Petzinger, John L. Stauffer, Frank Gilberg, Monica Bengus and Marlies Wijsenbeek. Eur Respir J 2018; 52: 1800230. | https://conductscience.org/library/papers/30287496 | PubMed |
| Comment in | 30072545 | Idiopathic pulmonary fibrosis: time for greater expectations? | https://conductscience.org/library/papers/30072545 | PubMed |
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21729893 | Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. | Chest | 2011 | https://conductscience.org/library/papers/21729893 | PubMed |
| 2 | 28257580 | A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly. | Am J Respir Cell Mol Biol | 2017 | https://conductscience.org/library/papers/28257580 | PubMed |
| 3 | 20935110 | Clinical course and prediction of survival in idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/20935110 | PubMed |
| 4 | 29313949 | Cancer statistics, 2018. | CA Cancer J Clin | 2018 | https://conductscience.org/library/papers/29313949 | PubMed |
| 5 | 24836312 | A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24836312 | PubMed |
| 6 | 26647432 | Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. | Eur Respir J | 2016 | https://conductscience.org/library/papers/26647432 | PubMed |
| 7 | 25439569 | Combination therapy: the future of management for idiopathic pulmonary fibrosis? | Lancet Respir Med | 2014 | https://conductscience.org/library/papers/25439569 | PubMed |
| 8 | 28889759 | Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. | Am J Respir Crit Care Med | 2018 | https://conductscience.org/library/papers/28889759 | PubMed |
| 9 | 27903663 | Beyond a single pathway: combination therapy in pulmonary arterial hypertension. | Eur Respir Rev | 2016 | https://conductscience.org/library/papers/27903663 | PubMed |
| 10 | 25504994 | Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. | Eur Respir J | 2015 | https://conductscience.org/library/papers/25504994 | PubMed |
| 11 | 21571362 | Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. | Lancet | 2011 | https://conductscience.org/library/papers/21571362 | PubMed |
| 12 | 24836310 | Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24836310 | PubMed |
| 13 | 21719092 | Idiopathic pulmonary fibrosis. | Lancet | 2011 | https://conductscience.org/library/papers/21719092 | PubMed |
| 14 | 21471066 | An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/21471066 | PubMed |
| 15 | 29212837 | Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. | Eur Respir Rev | 2017 | https://conductscience.org/library/papers/29212837 | PubMed |
| 16 | 26846335 | Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. | Respir Res | 2016 | https://conductscience.org/library/papers/26846335 | PubMed |
| 17 | 26915984 | Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. | Respir Med | 2016 | https://conductscience.org/library/papers/26915984 | PubMed |
| 18 | 24639005 | Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. | Adv Ther | 2014 | https://conductscience.org/library/papers/24639005 | PubMed |
| 19 | 26400368 | Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. | Respir Res | 2015 | https://conductscience.org/library/papers/26400368 | PubMed |
| 20 | 26177183 | An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. | Am J Respir Crit Care Med | 2015 | https://conductscience.org/library/papers/26177183 | PubMed |
Cited by66
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42676572 | Advances in pharmacotherapy for fibrotic interstitial lung disease. | Med Rev (2021) | 2026 | https://conductscience.org/library/papers/42676572 | PubMed |
| 42627051 | Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42627051 | PubMed |
| 42566145 | IGF2BP3 promotes early angiogenesis in pulmonary fibrosis by stabilizing HIF-1α. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42566145 | PubMed |
| 42509443 | Pirfenidone combined with nintedanib in connective tissue disease - associated interstitial lung disease with radiologic progression during antifibrotic monotherapy: A case series. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/42509443 | PubMed |
| 42325755 | Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42325755 | PubMed |
| 42085224 | Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. | Am J Respir Crit Care Med | 2026 | https://conductscience.org/library/papers/42085224 | PubMed |
| 41755466 | Viral Pathogens and Pulmonary Fibrosis: EMT-Driven Mechanisms and Insights From Traditional Chinese Medicine. | Rev Med Virol | 2026 | https://conductscience.org/library/papers/41755466 | PubMed |
| 41471790 | Recent Updates on Molecular and Physical Therapies for Organ Fibrosis. | Molecules | 2025 | https://conductscience.org/library/papers/41471790 | PubMed |
| 41372610 | Targeting gasdermin D-mediated pyroptosis: a precision anti-inflammatory strategy for acute and chronic lung diseases. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/41372610 | PubMed |
| 40917842 | New perspectives on the progression of pulmonary fibrosis: the cascade from aberrant microvascular endothelial cell activation to fibrosis. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40917842 | PubMed |
| 40323570 | Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons. | Pulm Ther | 2025 | https://conductscience.org/library/papers/40323570 | PubMed |
| 40226606 | Advances in idiopathic pulmonary fibrosis diagnosis and treatment. | Chin Med J Pulm Crit Care Med | 2025 | https://conductscience.org/library/papers/40226606 | PubMed |
| 40137966 | Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40137966 | PubMed |
| 40135237 | Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40135237 | PubMed |
| 40036154 | Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial. | Elife | 2025 | https://conductscience.org/library/papers/40036154 | PubMed |
| 39687964 | Photosensitive dermatitis caused by nintedanib in a patient of chronic fibrosing interstitial lung disease already on pirfenidone. | Indian J Pharmacol | 2024 | https://conductscience.org/library/papers/39687964 | PubMed |
| 39403408 | Understanding myofibroblast origin in the fibrotic lung. | Chin Med J Pulm Crit Care Med | 2024 | https://conductscience.org/library/papers/39403408 | PubMed |
| 39340742 | Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. | Pulm Ther | 2024 | https://conductscience.org/library/papers/39340742 | PubMed |
| 38948098 | Mesenchymal stem cells-extracellular vesicles alleviate pulmonary fibrosis by regulating immunomodulators. | World J Stem Cells | 2024 | https://conductscience.org/library/papers/38948098 | PubMed |
| 38655311 | Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases. | Heliyon | 2024 | https://conductscience.org/library/papers/38655311 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATHS | 470 | PubTator's text mining | https://conductscience.org/library/genes/470 | NCBI Gene |
| GGT1 | 2678 | PubTator's text mining | https://conductscience.org/library/genes/2678 | NCBI Gene |
| GGTLC5P | 653590 | PubTator's text mining | https://conductscience.org/library/genes/653590 | NCBI Gene |
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| PIRFENIDONE | CHEMBL1256391 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1256391 | ChEMBL |
| NINTEDANIB | CHEMBL502835 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL502835 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29946005
GET https://conductscience.org/api/papers/v1/29946005/references?page=2